Amag Pharmaceuticals Inc., of Waltham, Mass., reported record third quarter U.S. net sales of Feraheme (ferumoxytol), its iron deficiency anemia drug for patients with chronic kidney disease. Feraheme sales hit $22.5 million in the third quarter, up 20 percent compared to $19.3 million in the third quarter of 2013.